|
Powered by Cell Signaling Technology |
Site Information |
---|
NTSSTVQyStVVHsG SwissProt Entrez-Gene |
Blast this site against: NCBI SwissProt PDB |
Site Group ID: 448181 |
Associated spectra: 1 CST |
In vivo Characterization | |
---|---|
Methods used to characterize site in vivo: | |
Disease tissue studied: | |
Relevant cell line - cell type - tissue: |
Upstream Regulation | |
---|---|
Regulatory protein: | |
Treatments: |
Downstream Regulation | |
---|---|
Effects of modification on gp130: | |
Effects of modification on biological processes: | |
Induce interaction with: |
References | |
---|---|
Kim JW, et al. (2020) Engineering a potent receptor superagonist or antagonist from a novel IL-6 family cytokine ligand. Proc Natl Acad Sci U S A
32522868 Curated Info |
|
Cousins E, Gao Y, Sandford G, Nicholas J (2014) Human Herpesvirus 8 Viral Interleukin-6 Signaling through gp130 Promotes Virus Replication in Primary Effusion Lymphoma and Endothelial Cells. J Virol 88, 12167-72
25078695 Curated Info |
|
Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484 Curated Info |
|
Moritz A (2009) CST Curation Set: 5955; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info |
|
Guo A (2006) CST Curation Set: 1937; Year: 2006; Biosample/Treatment: cell line, Hs746T/-; Disease: pancreatic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info |
|
Stross C, et al. (2006) Oncostatin M receptor-mediated signal transduction is negatively regulated by SOCS3 through a receptor tyrosine-independent mechanism. J Biol Chem 281, 8458-68
16459330 Curated Info |
|
Anhuf D, et al. (2000) Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation. J Immunol 165, 2535-43
10946280 Curated Info |
|
Terstegen L, et al. (2000) The inhibition of interleukin-6-dependent STAT activation by mitogen-activated protein kinases depends on tyrosine 759 in the cytoplasmic tail of glycoprotein 130. J Biol Chem 275, 18810-7
10764798 Curated Info |
|
Nicholson SE, et al. (2000) Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A 97, 6493-8
10829066 Curated Info |
|
Bartoe JL, Nathanson NM (2000) Differential regulation of leukemia inhibitory factor-stimulated neuronal gene expression by protein phosphatases SHP-1 and SHP-2 through mitogen-activated protein kinase-dependent and -independent pathways. J Neurochem 74, 2021-32
10800945 Curated Info |
|
Schmitz J, et al. (2000) SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 275, 12848-56
10777583 Curated Info |
|
Ohtani T, et al. (2000) Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses. Immunity 12, 95-105
10661409 Curated Info |
|
Takahashi-Tezuka M, et al. (1998) Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol Cell Biol 18, 4109-17
9632795 Curated Info |